Significant Progress in core Portfolio Companies

RNS Number : 2522I

NetScientific PLC

24 March 2015

 

NetScientific plc

('NetScientific' or the 'Group')

NetScientific Full Year results: Significant Progress in core Portfolio Companies
Wanda Health and Vortex BioSciences.

First commercial launches expected during 2015

London, UK - 24 March 2015 - NetScientific (AIM: NSCI), the biomedical and healthcare group, announces its results for the year ended 31 December 2014. Highlights were as follows:

Highlights

·      Wanda Health - commercial roll-out of Congestive Heart Failure Clinical Decision Support Solution expected to commence in the US in H2 2015 with new contracts anticipated; CE mark also expected in H2 2015

·      Vortex BioSciences - cancer diagnostic technology being clinically assessed in multiple cancers by leading physicians and scientists; instruments expected to be shipped in H2 2015

·      Loss after tax of £7.1m (2013: loss £4.3m) reflecting development stage of portfolio

·      Available cash resources of £16.8m (at 31 December 2013: £25.5m)

·      Strategic partnership with Peter Thiel's Breakout labs and early funding made to four biomedical and healthcare technologies companies

·      Post year end, Farad Azima, CEO left the Group; Sir Richard Sykes appointed as Executive Chairman until a new CEO is appointed. Lady Barbara Judge stepping down as Non-Executive Director. Jonathan Paisner joined the board as a Non-Executive Director as representative of the Azima Family Trust.

·      Capital Markets Day planned for mid-year 2015

Sir Richard Sykes, Executive Chairman of NetScientific said:

"2014 has been a productive year for NetScientific, focusing on the growth plans of our lead portfolio companies, as well as seeking new investments, and establishing and building relationships with strategic partners.

In 2015, we anticipate commercial launches from our core portfolio companies, Wanda Health and Vortex BioSciences, further enhancing the value of our portfolio.

Post year end, we initiated a review of our portfolio and strategy and we will report the results by mid-year 2015."
 

- Ends -

Contact Details

NetScientific Peter Thoms, CFO	Tel: [phone]
Liberum (Nominated Advisor) Clayton Bush Christopher Britton	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Tim Watson	Tel: [phone] Email: [e-mail]

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society. For more information, please visit the website at www.NetScientific.net

CHAIRMAN'S STATEMENT

Overview

The year ended 31 December 2014 has been a productive one for NetScientific plc ('NetScientific' or 'the Group'). In accordance with the Group's business strategy, NetScientific has been supporting its lead portfolio companies' growth plans, seeking new companies and technologies for investment, and establishing and building relationships with strategic partners and collaborators.

The Group made a loss after tax of £7.1m (2013: loss £4.3m) which is a reflection of the business model where a number of the portfolio companies are trading subsidiaries developing their technologies. The net cash position at the year end of £16.1m is available for the Group's working capital requirements, additional investment in the current portfolio and future investment opportunities.

Within the portfolio, the focus has been primarily on the two most mature companies, Wanda Health (Wanda) and Vortex BioSciences (Vortex), which have been making good progress towards their anticipated first commercial launches in 2015. There are another three core companies within the portfolio - Glucosense, Glycotest and ProAxsis, which are exciting opportunities, ready for accelerated development through further investment in the coming year. More detail is included in the Portfolio Review.

Post year end, there has been a change in the management team resulting in a review of the investment strategy and overall portfolio. The results of this review will be presented at a detailed Capital Markets Day in mid-2015 where investors will also be able to meet with and receive an update on the portfolio companies.

Looking forward to the coming year, the Group is expecting progress across the portfolio with some significant value inflection points. A specific focus is on the core companies with commercial launches of Wanda's CHF Clinical Decision Support Solution and Vortex's VX-1 Instrument expected.

Financial Results

The Group made a loss after tax for the year ended 31 December 2014 of £7.1m (31 December 2013: £4.3m).

The cash outflow from the operating activities for existing companies and projects before changes in working capital was £5.8m and further £2.4m was invested in capital investment and funding positions in new pipeline companies and projects.

Net funds held by the Group at 31 December 2014 amounted to £16.1m and comprised cash and cash equivalents and short-term deposits of £16.8m less long-term loans of £0.7m.

Business Strategy

NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.

NetScientific is primarily focused on opportunities targeting the increased numbers of patients living with chronic diseases and the associated costs, the key challenge for the global healthcare sector. Consequently, the areas of focus represent highly attractive growth markets where breakthrough technology solutions are in high demand. The three key areas of focus are digital health (data analytics, wearable technologies and devices), diagnostics and therapeutics.

New pipeline investments are sourced from leading researchers from the US and European universities, or through strategic partnerships, backing entrepreneur-led start-ups with ground breaking technologies. In addition the pipeline can be enhanced by new projects originating from the team's considerable sector expertise and network.

NetScientific has typically taken a controlling interest in its portfolio companies, which it aims to maintain for as long as practical commensurate with the needs of the company and management of the portfolio. The Group is an active investor providing extensive management support. This involves the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.

The aim of the Group is to maintain, at any one time, a portfolio of three to five actively managed companies and a secondary portfolio of 10 smaller investments, the most successful of which will become more actively managed companies. As at 31 December 2014, the Group had a portfolio of 15 investments.

NetScientific will continue to invest in its portfolio to maximise shareholder return in the form of capital growth. However, there are no fixed targets for the length of time during which an investment may be held, as this will be dependent both on progress and availability of funding. This means that no realisation of assets will be attempted until optimum value has been developed through achievement of key technical and commercial milestones usually reflected in regulatory approvals or commercial traction. The Board will, however, actively manage the portfolio with a view to maximising shareholder value and generating funds for re-investment in the pipeline.

Portfolio Review

The next section highlights the core five actively managed companies and which the Board considers are making good progress and show significant promise in the short to medium term.

Wanda Health

Wanda Health is developing cloud-based analytics, as part of a total patient management solution, in partnership with other healthcare providers. The core analytics engine is based on 12 years of research at the Wireless Health Institute at UCLA.

Wanda Health completed development of a predictive analytics engine for use in remotely monitoring patients with Congestive Heart Failure ('CHF'), the leading cause of hospital re-admissions in USA.

During the first half 2014, the company was pursuing regulatory approval in both the US and Europe, and preparing for commercial launch. However, in second half 2014 it became clear that the US regulatory environment had changed and clinical decision support systems no longer required FDA approval before marketing. Therefore, commercial roll out is commencing in hospitals and managed care providers in USA, and the Group expects to announce new contracts in the coming year.

In Europe, Wanda Health has been focused on achieving a CE mark, which is expected early in the second half 2015. In addition, working with a partner in the UK, there are plans to complete a pilot with a clinical commissioning group with a view to a commercial roll out later in 2015

Work on other applications, notably in patients with co-morbidities in addition to CHF, has been progressing well and is expected to be ready for beta testing in the second half of 2015 and launch in late 2015.

Vortex

Vortex BioSciences is a cancer diagnostic instrument company providing liquid biopsy solutions for isolating, detecting and harvesting circulating tumour cells ('CTCs') from cancer patients' blood samples.

The company is developing the Vortex VX-1 benchtop instrument, which runs a simplified, high-speed blood test for a wide range of metastatic cancers. The instrument harvests live CTCs from patient blood samples for use in downstream clinical applications such as monitoring disease progression and drug treatment effectiveness. Revenue will be generated by selling laboratory instruments along with single use cartridges for each blood sample.

During 2014, clinical evaluations have been initiated by leading cancer physicians and scientists, working in the fields of lung, breast, prostate, pancreatic and colon cancers at the UCLA Medical Center, Stanford Hospital, the Rowland Institute at Harvard University and at further leading university cancer centers.

Post year end, the first instruments for the research market are being finalised and will be shipped to collaborators. These instruments do not require FDA approval and shipments are expected in the second half of 2015.

Glycotest

Glycotest is developing diagnostic tests designed to support the accurate diagnosis of liver disease, liver cancers and fibrosis-cirrhosis, and ultimately help improve disease management in patients.

The technology was spun-out of the Drexel University College of Medicine and the Baruch S. Blumberg Institute. The first diagnostic panel under development, measures serum levels of multiple liver proteins using the company's proprietary technology to detect early stage Hepatocellular Carcinoma ('HCC'), improving surveillance of the disease in high-risk populations.

In October 2014, Glycotest entered research collaboration with Nottingham-based Oncimmune Ltd, to explore the combined application of Oncimmune's proprietary autoantibody technology and Glycotests' glycoprotein biomarkers, for the early detection of liver cancer.

The company is currently working on panel development and validation in anticipation of commercial launch in late 2016.

Glucosense

Glucosense is developing a non-invasive blood glucose sensor, which has a number of potential professional and consumer applications. These include as a partial replacement for the finger-prick testing, continuous non-invasive glucose monitoring and as a wearable hypoglycaemia-alert device.

The company has commenced development of a next generation prototype which will allow further clinical testing in late 2015, early 2016. The technology is also attracting strong interest from a number of global technology companies. Glucosense is in early stage discussions with potential partners for co-development or out-licensing of the technology in certain applications. The focus in 2015 will be on continuing to advance product development.

ProAxsis

In February 2014, NetScientific invested in ProAxsis, a spin-out from Queen's University Belfast which has novel technology in detection of activated proteases (ProteaseTags^TM) which are central to a range of diseases.

The company is developing a range of novel, point of care, easy to use tests, which will enable routine monitoring and improved management of patients with chronic conditions, such as cystic fibrosis and chronic obstructive pulmonary disease. The lead product, NEATstick^TM, detects active neutrophil elastase, which is an early indicator of lung infection in patients with cystic fibrosis. In parallel with this, ProAxsis is also developing a range of activity-base immunoassays, which will assist the research community in the specific measurement of activated protease disease-biomarkers. Later in 2015, the launch of the first ProteaseTags^TM immunoassay tests is anticipated as well as the completion of pre-clinical development of NEATstick^TM.

New Investments

A key evolution of the Group's approach to building the pipeline occurred in March 2014 with the strategic partnership with San Francisco-based, Breakout Labs. This is Peter Thiel's revolving philanthropic fund that supports early-stage companies working on technological breakthroughs.

Under the terms of the agreement, NetScientific will follow on Breakout Labs' initial investment in those biomedical and healthcare technologies companies that fit NetScientific's investment strategy of funding technologies that offer transformative benefits to people lives and society.

During 2014 an equity investment was made in CytoVale and loan funding (convertible loan notes) was provided to Longevity Biotech, G-Tech Medical and Epibone. In addition to NetScientific's commercial and scientific due diligence all these companies have been positively assessed by Breakout Labs' appraisal system that selects only a few of the entrepreneur led companies applying.

PDS Biotechnology

In December 2014, NetScientific invested in PDS Biotechnology ('PDS'). This reflects an emerging strategy to identify selective opportunities in next generation therapeutics. PDS is a clinical stage immunotherapy company developing a next-generation of simpler, safer and more effective immunotherapies for cancer and infectious disease. Versamune®, its novel synthetic nanoparticle platform technology, activates multiple immunological mechanisms which direct the targeting of cancer and infectious disease by the immune system.

The company's lead product, PDS0101, is in phase I clinical trials in the US for HPV-related cancers. PDS has licensed the Versamune® technology to Merck KGaA for use in two early stage cancer immunotherapy programmes. The company has also ongoing pre-clinical programmes for other cancers as well as pandemic influenza.

Post year: management changes

At the beginning of 2015, Farad Azima, the CEO, left the Group and Sir Richard Sykes took on the role of Executive Chairman until a new CEO is appointed. As outlined below, Farad Azima is becoming Executive Chairman of Frontierbio Sciences Limited ('Frontierbio'), a company jointly owned by the Group.

The search for a new CEO is underway. Until a new candidate is found, responsibilities have been organised geographically. Dr. Mike Boyce-Jacino now manages all USA investments and David Gough now manages European investments. Both directors have extensive life sciences experience; Dr. Mike Boyce-Jacino was a founder of Orchid Biosciences, Inc. and Vice President at Beckman Coulter, Inc. and David Gough was formerly Head of Healthcare and Biotechnology at PA Consulting Group, a founder of Vectura Group plc and a healthcare venture capitalist.

On 26 February 2015, NetScientific announced that Jonathan Paisner would join the board as a Non-Executive Director. He is being appointed by the Azima family trusts pursuant to their rights under the NetScientific Articles of Association to nominate a director.

Lady Barbara Judge stepped down on 23 March 2015. She was recently elected as Chairman of the Institute of Directors and is reducing her other commitments. A search is underway for a replacement Non-Executive Director.

Post year end: Related party transaction

As part of the Group's ongoing review of its portfolio, the Board has agreed to reduce its commitment but retain an interest in certain projects that fall outside its core area of focus. The projects relate to three sponsored research agreements with Leuven University, Belgium (the 'SRAs') and its 38% shareholding in DName-iT NV, a Belgian company, part owned by Leuven University, which were announced to the market on 7 January 2015.

The Group has agreed to transfer these projects (including its DName-iT NV shareholding) to a new company, Frontierbio. On completion of this transfer Frontierbio will be controlled by Zahra Holdings Limited ('Zahra'), a company wholly-owned by a family trust of the former CEO, Farad Azima, which together with two other companies controlled by Azima family trusts, holds 47.8% of the shares in NetScientific (in addition Farad Azima has a personal holding of 0.4%). Zahra will own 50.01% of the equity in Frontierbio, with the remaining equity held by the Group.

As part of a shareholders' agreement dated 23 March 2015 between Zahra and NetScientific UK Limited ('NUK'), a wholly-owned NetScientific subsidiary, the parties have committed funding to Frontierbio on completion to the value of £1.8m. Zahra, through its ownership of Frontierbio, will assume 50.01% of this funding commitment (£0.9m). NUK's funding commitment (£0.9m) will be satisfied by the c.£0.53m it has already spent to date on the SRAs and DName-it shareholding (some of which will be capitalised as equity in Frontierbio and the rest converted into debt) and a commitment to transfer a further c.£0.37m on completion.. The combined new funding of c.£1.27m provided on completion will be used to (a) acquire a controlling shareholding in DName-iT NV and (b) satisfy payment obligations under the SRAs. Funding beyond this £1.27m is discretionary for both parties.

Under the shareholders' agreement day to day operational control of Frontierbio will be with its board of directors (of which a majority will be appointed by Zahra and the Executive Chairman of Frontierbio will be Farad Azima), subject to reserved shareholder rights in favour of NUK. Instead of receiving a salary as Executive Chairman of Frontierbio for the following two years, Farad Azima can receive up to 5% share options in Frontierbio (but not exercisable until after that two year period).

On its IPO, NetScientific entered into a relationship agreement with the three Azima family trusts, which through controlled companies (including Zahra) hold shares in NetScientific, to regulate the ability of NetScientific and its subsidiaries to act independently of those trusts and controlled companies. NetScientific has agreed an amendment with the parties to the relationship agreement to allow Zahra to enter into and perform its obligations under the shareholders' agreement with NUK.

As Zahra, Farad Azima and his family trusts are related parties under the AIM Rules for Companies, the Directors (Jonathan Paisner abstaining by virtue of being appointed a director on the nomination of the Azima family trusts) consider, having consulted with Liberum in its capacity as the Company's nominated adviser, that the shareholders' agreement terms and the relationship agreement amendment are fair and reasonable insofar as NetScientific shareholders are concerned.

Finally, we would like to thank all our staff for their hard work and commitment to NetScientific. We have made considerable progress in 2014 and look forward to another exciting year.

Sir Richard Sykes

Chairman

24 March 2015

CONSOLIDATED INCOME STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2014

	Notes	2014 £		2013 £
Other operating income		343,126		177,667
Research and development expenditure Other administrative expenses Share-based payments Impairment of intangible assets Reorganisation and AIM listing costs	5	3,674,939 2,535,028 717,001 641,767 -		762,624 1,900,242 717,234 - 1,123,508
Total administrative expenses		(7,568,735)		(4,503,608)
Loss from operations		(7,225,609)		(4,325,941)
Finance income		77,465		37,566
Finance expense		(45,671)		(35,210)
Share of loss of associates and joint venture		(119,991)		(27,832)
Loss before taxation		(7,313,806)		(4,351,417)
Income tax credit		187,008		14,153
Loss for the year		(7,126,798)		(4,337,264)
Loss attributable to:
Owners of the parent		(6,425,011)		(4,112,565)
Non-controlling interests		(701,787)		(224,699)
		(7,126,798)		(4,337,264)
Basic and diluted loss per ordinary share	4	(17.9)p		(21.0)p

CONSOLIDATED INCOME STATEMENT AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2014

		2014 £		2013 £
Loss for the year		(7,126,798)		(4,337,264)
Items that may be subsequently reclassified to profit or loss:
Exchange differences on translation of foreign operations		295,989		87,377
Total comprehensive loss for the year		(6,830,809)		(4,249,887)

Attributable to:
Owners of the parent		(6,129,022)		(4,025,188)
Non-controlling interests		(701,787)		(224,699)
		(6,830,809)		(4,249,887)

All other comprehensive income will be reclassified to retained earnings on the ultimate sale of any relevant subsidiary company.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2014

	Notes	2014 £		2013 £
ASSETS
NON-CURRENT ASSETS
Intangible assets	5	10,244		638,492
Property, plant and equipment		348,245		67,101
Investments in equity accounted associates	6a	228,883		-
Investments in equity accounted joint ventures	6b	-		69,872
Available for sale investments	6c	1,806,608		2
Derivative financial assets	7	100,159		-
Other receivables		545,606		18,905
		3,039,745		794,372
CURRENT ASSETS
Trade and other receivables		853,022		306,746
Cash and cash equivalents		16,867,198		25,546,951
		17,720,220		25,853,697
TOTAL ASSETS		20,759,965		26,648,069
LIABILITIES CURRENT LIABILITIES
Trade and other payables		(1,281,242)		(1,113,490)
Loans and borrowings		(43,250)		(3,250)
		(1,324,492)		(1,116,470)
NON CURRENT LIABILITIES
Trade and other payables		(52,537)		(49,723)
Loans and borrowings		(687,369)		(475,109)
Provision for deferred tax		-		(106,965)
		(739,906)		(1,748,537)
TOTAL LIABILITIES		(2,064,398)		(2,865,277)
TOTAL NET ASSETS		18,695,567		24,899,532
ISSUED CAPITAL AND RESERVES ATTRIBUTABLE TO THE PARENT
Called up share capital		1,795,101		1,795,101
Share premium account		30,844,552		30,844,552
Capital reserve account		236,745		236,745
Foreign exchange reserve		446,120		150,131
Retained earnings		(13,529,442)		(7,459,726)
Equity attributable to the owners of the parent		19,793,076		25,566,803
Non-controlling interests		(1,097,509)		(667,271)
TOTAL EQUITY		18,695,567		24,899,532

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2014
	Shareholders' equity
	Share capital £	Share premium £	Capital reserve £	Retained earnings £		Foreign exchange reserve £		Total £		Non- controlling interests £	Total equity £
Balance at 1 January 2013	1	-	-	(4,064,395)		62,754		(4,001,640)		(242,036)	(4,243,676)
Comprehensive Income
Loss for the year	-	-	-	(4,112,565)		-		(4,112,565)		(224,699)	(4,337,264)
Other comprehensive income	-	-	-	-		87,377		87,377		-	87,377
Acquisition of subsidiary	-	-	-	-		-		-		(203,357)	(203,357)
Increase in subsidiary shareholding	-	-	-	-		-		-		(6,772)	(6,772)
Dilution in subsidiary shareholdings	-	-	-	-		-		-		9,593	9,593
Issue of share capital	1,795,100	32,279,998	-	-		-		34,075,098		-	34,075,098
Transaction costs in respect of share issues	-	(1,435,446)	-	-		-		(1,435,446)		-	(1,435,446)
Waiver of loan interest on share issue	-	-	236,745	-		-		236,745		-	236,745
Share-based payments	-	-	-	717,234		-		717,234		-	717,234
Total comprehensive income	1,795,100	30,844,552	236,745	(3,395,331)		87,377		29,568,443		(425,235)	29,143,208
Balance at 1 January 2014	1,795,101	30,844,552	236,745		(7,459,726)		150,131		25,566,803	(667,271)	24,899,532
Comprehensive Income
Loss for the year	-	-	-		(6,425,011)		-		(6,425,011)	(701,787)	(7,126,798)
Other comprehensive income	-	-	-		-		295,989		295,989	-	295,989
Acquisition of subsidiaries	-	-	-		-		-		-	78,580	78,580
Increase in subsidiary shareholding	-	-	-		(489,893)		-		(489,893)	489,893	-
Dilution in subsidiary shareholding	-	-	-		128,187		-		128,187	(128,187)	-
Disposal of subsidiaries	-	-	-		-		-		-	2,785	2,785
Foreign exchange differences	-	-	-		-		-		-	(171,522)	(171,522)
Share-based payments	-	-	-		717,001		-		717,001	-	717,001
Total comprehensive income	-	-	-		(6,069,716)		295,989		(5,773,727)	(430,238)	(6,203,965)
Balance at 31 December 2014	1,795,101	30,844,552	236,745		(13,529,442)		446,120		19,793,076	(1,097,509)	18,695,567

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2014

		2014 £		2013 £
Cash flows from operating activities
Loss before income tax		(7,313,806)		(4,351,417)
Adjustments for:
Depreciation of property, plant and equipment		65,981		5,508
Amortisation of intangible assets		1,614		1,616
Loss on disposal of property, plant and equipment		768		-
Share of loss of associates and joint venture		119,991		27,832
Impairment of intangible assets		641,767		-
Share-based payments		717,001		717,234
Finance income		(77,465)		(37,566)
Finance costs		45,671		35,210
		(5,798,478)		(3,601,583)

Changes in working capital:
Increase in trade and other receivables		(962,051)		(245,100)
Increase in trade and other payables		129,757		167,977
Cash used in operations		(6,630,772)		(3,678,706)
Income tax received		19,399		-
Net cash used in operating activities		(6,611,373)		(3,678,706)
Cash flows from investing activities
Investment in joint venture		(35,119)		(60,354)
Investment in associate		(239,189)		-
Cash acquired on acquisition of subsidiary		52,000		1,973
Purchase of available for sale investments		(1,806,606)		-
Purchase of derivative financial assets		(100,159)		-
Purchase of property, plant and equipment		(337,469)		(60,861)
Proceeds from sale of property, plant and equipment		1,054		-
Interest received		66,661		37,566
Increase shareholding in subsidiary undertaking		-		(6,772)
Net cash used in investing activities		(2,398,827)		(88,448)
Cash flows from financing activities
Proceeds from loans		190,000		428,457
Proceeds from share issue Share issue cost		- -		29,912,750 (1,435,446)
Net cash from financing activities		190,000		28,905,761
(Decrease) / increase in cash and cash equivalents		(8,820,200)		25,138,607
Cash and cash equivalents at beginning of year		25,546,951		410,788
Exchange gains / (losses) on cash and cash equivalents		140,447		(2,444)
Cash and cash equivalents at end of year		16,867,198		25,546,951

NOTES TO THE FINANCIAL INFORMATION FOR THE YEAR ENDED 31 DECEMBER 2014

1.             General Information

The Company is a public limited company incorporated on 12 April 2012 and domiciled in England with registered number 08026888 and its shares are listed on the Alternative Investment Market (AIM) of the London Stock Exchange.

2              Basis of preparation

The preliminary results of the year ended 31 December 2014 have been extracted from audited accounts which have not yet been delivered to the Registrar of Companies.

The Financial Statements set out in this announcement do not constitute statutory accounts for the year ended 31 December 2014.

The report of the auditors on the statutory accounts for the year ended 31 December 2014 was unqualified and did not contain a statement under Section 498 of the Companies Act 2006. The Financial Statements for the year ended 31 December 2014 included in this announcement were authorised for issue in accordance with a resolution of the Board of Directors on 23 March 2015.

The Company is a limited liability company incorporated and domiciled in England & Wales and whose shares are quoted on AIM, a market operated by The London Stock Exchange.

3.             Significant accounting policies

The Group's financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRS') as adopted by the European Union as they apply to the financial statements of the Group for the year ended 31 December 2014.

While the financial information included in this preliminary announcement has been prepared in accordance with IFRS, this announcement does not in itself contain sufficient information to comply with IFRS.

4.             LOSS PER SHARE

Basic loss per share is calculated by dividing the loss for the financial year attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year.

Diluted loss per share is calculated using the weighted average number of shares adjusted to assume the conversion of all dilutive potential ordinary shares.

		2014 £		2013 £
Loss attributable to equity holders of the company		(6,425,011)		(4,112,565)
Weighted average number of ordinary shares in issue		35,902,020		19,558,458

The loss attributable to ordinary shareholders and weighted average number of ordinary shares for the purpose of calculating the diluted loss per ordinary share are identical to those used for basic loss per share. Whilst the parent company has share options in existence they are not dilutive as their exercise would have the effect of reducing the loss per ordinary share.

5.         INTANGIBLE ASSETS

	Goodwill £		In process research and development £		Patents and licences £		Total £
COST At 1 January 2013	-		-		15,230		15,230
Additions	359,220		267,414		-		626,634
At 31 December 2013	359,220		267,414		15,230		641,864
Exchange Adjustments	-		15,133		-		15,133
At 31 December 2014	359,220		282,547		15,230		656,997
AMORTISATION At 1 January 2013	-		-		1,756		1,756
Exchange adjustments	-		-		-		-
Charge for the year	-		-		1,616		1,616
At 31 December 2013	-		-		3,372		3,372
Charge for the year	-		-		1,614		1,614
Impairment charge (i)	359,220		282,547		-		641,767
At 31 December 2014	359,220		282,547		4,986		646,753
NET BOOK VALUE
At 31 December 2014	-		-		10,244		10,244
At 31 December 2013	359,220		267,414		11,858		638,492
At 31 December 2012	-		-		13,474		13,474

(i)         The goodwill and in process research and development arose on the acquisition of Qlida Diagnostics, Inc. Following the review of the Group's strategy and portfolio to focus on core projects and the uncertainty and timing of the commercialisation of the underlying technology an impairment charge based on value in use was made during the year, which has been recognised in the consolidated income statement.

6.         INVESTMENTS

(a)        Associates

	2014 £
At 1 January	-
Additions	239,189
Loss after tax recognised in the consolidated income statement	(10,306)
At 31 December	228,883

Set out below is the associate of the Group as at 31 December 2014:

Name	Country of incorporation	Place of business	% of ownership interest		Measurement method
			2014	2013
DName - iT NV	Belgium	Belgium	38%	-	Equity

DName-iT BV is developing solutions to improve the quality and workflow on next generation genetic sequencing diagnostic tests.

(b)        Joint venture

Interest in joint venture

The Group has a 50% interest in a jointly controlled entity, Butterfly BioSciences LLC, which has been included in the consolidated accounts using the equity method. Butterfly BioSciences LLC is an early-stage drug discovery company that employs a proprietary random library-based technology for the discovery of novel RNAi drugs with innovative targeting properties and improved therapeutic indices, its principal place of business is the USA. Following the review of the Group's strategy and portfolio to focus on core projects and the uncertainty and timing of the commercialisation of the underlying technology an impairment charge has been made.

	2014 £		2013 £
At 1 January	69,872		37,350
Exchange adjustments	4,694		-
Additions	35,119		60,354
Loss after tax recognised in the consolidated income statement	(17,805)		(27,832)
Impairment charge	(91,880)		-
At 31 December	-		69,872

(c)        Available for sale investments

Represent unquoted equity securities
		2014 £		2013 £
At 1 January		2		2
Additions		1,806,606		-
At 31 December 2014		1,806,608		2

Name	Country of incorporation	% of issued share capital	Currency denomination	£
PDS Biotechnology Corporation	USA	14.85%	US$	1,657,030
CytoVale, Inc.	USA	2.15%	US$	149,576
Other				2
				1,806,608

The Company acquired its investments in PDS Biotechnology Corporation on 15 December 2014 and its investment in CytoVale, Inc. in March 2014. In the opinion of the Directors the fair value of these investments at year end equates to their cost.

7.         DERIVATIVE FINANCIAL ASSETS

		2014 £		2013 £
Warrants		100,159		-

The Group have warrants to acquire equity shares in PDS Biotechnology Corporation at an agreed price at any time prior to 15 December 2016. The warrants have been valued using the Black-Scholes Model.

 

END

 

 

FR XXLLLEXFFBBQ